New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 22, 2013
15:11 EDTABTEarnings Preview: Abbott's Q4 will be last to include proprietary pharma
Abbott Laboratories (ABT) is scheduled to report Q4 earnings before the market open on Wednesday January 23, with a conference call scheduled for 9:00 am ET. Abbott is engaged in the discovery, development, manufacture, and sale of health care products worldwide. The company recently separated its proprietary pharmaceutical business into AbbVie, an independent company... EXPECTATIONS: Analysts are looking for EPS of $1.50 on revenue of $10.58B, according to First Call. The consensus range for EPS is $1.47-$1.53 on revenue of $10.40B-$10.76B... LAST QUARTER: Abbott reported Q3 EPS of $1.30 against estimates of $1.28 on revenue of $9.77B against estimates of $9.93B. On its Q3 earnings conference call the company said it was too early to give FY13 guidance... STREET RESEARCH: On January 11, Barclays initiated Abbott with an Equal Weight and a $35 price target. Earlier in January, Deutsche Bank downgraded Abbott to Hold from Buy with a $33 price target citing valuation following the spin-off of AbbVie, while Wells Fargo in a research note on January 2 said Abbott shares are attractive following the spin-off, citing significant margin expansion opportunities. Wells Fargo gave a valuation range on Abbott shares of $33-$34 to reflect the spin-off... PRICE ACTION: Shares of Abbott traded in an upward trajectory in 2012 from approximately $56.50 to a high of approximately $72 reached in mid-October. Abbott has traded in a range of approximately $31.64 to $33.88 since the company announced the completion of the spin-off on January 2.
News For ABT From The Last 14 Days
Check below for free stories on ABT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2014
13:54 EDTABTDanone slips after fresh dairy volume shrinks
Subscribe for More Information
09:35 EDTABTAbbott: We have plenty of cash for M&A activity, not constrained on borrowing
09:15 EDTABTAbbott sees pace of EPS growth and sales to accelerate throughout FY14
Subscribe for More Information
09:14 EDTABTAbbott sees Q2 EPS 50c-52c, consensus 51c
Sees Q2 sales growth in low to mid single digits, consensus $5.54B.
09:13 EDTABTAbbott sees accelerating sales growth in 2H14
Subscribe for More Information
07:49 EDTABTAbbott expects to increase global capacity to meet demand in 2014
Expects three new manufacturing facilities scheduled to come on line in China, India and the U.S. in Q2. Adult Nutrition remains on track to achieve an operating margin ratio of more than 20 percent of sales by 2015.
07:47 EDTABTAbbott completes enrollment in U.S., China, Japan in Absorb regulatory trials
Subscribe for More Information
07:46 EDTABTAbbott backs FY14 adjusted EPS $2.16-$2.26, consensus $2.20
07:46 EDTABTAbbott reports Q1 adjusted EPS 41c, consensus 36c
Subscribe for More Information
April 15, 2014
15:19 EDTABTNotable companies reporting before tomorrow's open
Subscribe for More Information
14:14 EDTABTEarnings Preview: Abbott's established pharmaceuticals sales in focus
Subscribe for More Information
April 14, 2014
09:05 EDTABTAbbott announces FDA clearance for test to diagnose diabetes
Subscribe for More Information
April 10, 2014
08:34 EDTABTAbbott completes enrollment of Absorb clinical trials in U.S., Japan and China
Subscribe for More Information
April 9, 2014
11:43 EDTABTGilead defended by analysts after recent pullback
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use